Epivir 3TC nucleoside analog data

Based on the recommendation of the independent Data Safety and Monitoring Board, a study to determine the effect of 3TC therapy on survival or delay in disease progression was stopped early after an interim analysis showed a 54 percent reduction in progression to AIDS or death for patients who had 3TC in their treatment regimen, versus placebo.

The CAESAR study began in March 1995 and was scheduled to end in March 1997. It was designed to add 3TC to patients' existing therapy, or adding 3TC to AZT in patients who weren't on therapy at study entry. The most common existing therapy among patients enrolling in the study was AZT alone. Other regimens at entry were AZT plus ddI or AZT plus ddC. Patients had CD4 counts of 25-250 at entry. ...